Filing Flows › ImmunityBio (IBRX) › Q2 2026 › vs Q1 2026
ImmunityBio (IBRX) Q2 2026 vs Q1 2026 (quarter over quarter)
ImmunityBio's revenue rose $7.0M (+16%) from $44.2M in Q1 2026 to $51.2M in Q2 2026. The biggest changes: Product revenue, net +$6.5M (+15%); Other revenues +$529K (15×).
ImmunityBio, Q2 2026: revenue $51.2M (+94% year over year), operating margin -120.4%, net loss $230M, operating cash flow −$66.5M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $50.7M | $44.2M | $6.5M | +15% |
| Other revenues | $568K | $39K | $529K | 15× |
| Revenue | $51.2M | $44.2M | $7.0M | +16% |
| Net loss | $230M | $633M | −$402M | -64% |
| Costs & expenses | $282M | $677M | −$395M | -58% |
| Operating costs | $113M | $114M | −$1.1M | -0.9% |
| Interest & other, net | $169M | $563M | −$394M | -70% |
| Cost of revenue | $298K | $238K | $60K | +25% |
| Other operating costs | $113M | $114M | −$1.1M | -1% |
| Operating cash sources | $230M | $633M | −$402M | -64% |
| Depreciation & amortization | $4.4M | $4.4M | $27K | +0.6% |
| Share-based compensation | $8.5M | $8.2M | $349K | +4% |
| Working capital & other | $151M | $545M | −$394M | -72% |
| Cash used in operations | $66.5M | $75.4M | −$8.9M | -12% |
| Net loss absorbed | $230M | $633M | −$402M | -64% |
Questions
How much did ImmunityBio's revenue grow quarter over quarter in Q2 2026?
ImmunityBio's revenue rose $7.0M (+16%) from $44.2M in Q1 2026 to $51.2M in Q2 2026.
What drove ImmunityBio's revenue change in Q2 2026?
Product revenue, net +$6.5M (+15%); Other revenues +$529K (15×).